- Datum16.05.2025
- UhrzeitLäuft gerade
- Veranstalter
XTB
Kein Moderator verfügbar
Clinuvel Pharmaceuticals Ltd. Aktie
Verkaufen
Kaufen
Clinuvel Pharmaceuticals Ltd. Chart
Clinuvel Pharmaceuticals Ltd. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
-0,49 %
Intraday
-5,06 %
1 Woche
3,13 %
1 Monat
-14,87 %
Seit Jahresbeginn
-33,82 %
1 Jahr
-45,29 %
3 Jahre
-51,76 %
5 Jahre
170,89 %
10 Jahre
Passender Service zu Clinuvel Pharmaceuticals Ltd.
Webinar zu Clinuvel Pharmaceuticals Ltd.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)4,800-10,700
- Jahrestief / Hoch (€)4,800-7,695
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Clinuvel Pharmaceuticals Ltd.
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| 05.09.2024 | 2024 | 0,05 $ | 0,33 % |
| 05.09.2023 | 2023 | 0,05 $ | 0,28 % |
| 06.09.2022 | 2022 | 0,04 $ | 0,21 % |
| 02.09.2021 | 2021 | 0,025 $ | 0,07 % |
| 03.09.2020 | 2020 | 0,025 $ | 0,12 % |
| 04.09.2019 | 2019 | 0,025 $ | 0,10 % |
| 21.09.2018 | 2018 | 0,02 $ | 0,11 % |
Termine von Clinuvel Pharmaceuticals Ltd.
Keine aktuellen Termine
Beschreibung
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
